📰 Pharma Partnering News
Page 2 - Pharma Partnering News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Pharma Partnering. Real-time updates on events, politics, business and more.
August 3, 2022
Leveraging Poseidas novel approach to cell therapy and Roches expertise in developing and commercializing therapies to transform cancer care, the...
June 4, 2022
Repare Therapeutics announces it’s going to collaborate with Roche and stock prices rise by 25%
May 23, 2022
/PRNewswire/ -- KaliVir Immunotherapeutics, Inc. today announced a collaboration and global exclusive licensing agreement with Roche for the discovery,...
May 23, 2022
/PRNewswire/ -- KaliVir Immunotherapeutics, Inc. today announced a collaboration and global exclusive licensing agreement with Roche for the discovery,...
March 29, 2022
BIO-Europe Spring is one of Europe's biggest biotech partnering events with discussion topics ranging from platform technologies and manufacturing to biotech investments. Here are some of the key take-home reports from the proceedings, published as they happen.
December 8, 2021
Roche and its Genentech subsidiary have committed up to $12 billion to Recursion in return for using its Recursion Operating System (OS) to advance therapies in 40 programs that include “key areas” of neuroscience and an undisclosed oncology indication.
May 25, 2021
Pieris Pharmaceuticals Announces Respiratory and Ophthalmology Collaboration with Genentech ACCESSWIRE 25 May 2021, 22:05 GMT+10 Pieris will receive $20 million as an upfront payment and is eligible to receive more than $1.4 billion in additional potential milestone payments plus royalties for commercialized programs Collaboration includes initial programs in respiratory disease and ophthalmology, with opportunity to nominate additional programs BOSTON, MA / ACCESSWIRE / May 25, 2 021 / Pieris...
January 7, 2021
Ribometrix Announces Collaboration with Genentech to Discover and Develop RNA-Targeted Small Molecule Therapeutics Ribometrix Announces Collaboration with Genentech to Discover and Develop RNA-Targeted Small Molecule Therapeutics Ribometrix, Inc., today announced a strategic collaboration with Genentech, a member of the Roche Group, to discover and develop novel RNA-targeted small molecule therapeutics against several targets. Ribometrix is focused on leveraging its RNA structural expertise...
January 6, 2021
Genentech Launches $1B+ RNA Collaboration with Ribometrix Ribometrix has shown that several RNAs associated with disease contain structural pockets—clefts and crevices (highlighted)—that are amenable to targeting with small molecules. Genentech, a member of the Roche Group, will apply Ribometrix’s discovery platform to discover, develop and commercialize small molecule drug candidates against RNA targets, through a collaboration that could generate more than $1 billion for the Durham, NC...